Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.58 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267462 | 0.87 | CACNA1G (0.77) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5265839 | 0.86 | CACNA1G (0.75) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5265417 | 0.86 | CACNA1G (0.75) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL8429638 | 0.85 | CACNA1G (0.73) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL26330969 | 0.82 | CACNA2D1 (0.81) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL28804531 | 0.80 | CACNA1G (0.67) | CACNA1GGAANPSR1LMNA | |
| SCHEMBL7394034 | 0.80 | CACNA1G (0.66) | CACNA1GGAANPSR1LMNA | |
| SCHEMBL3859810 | 0.77 | KDM4E (0.64) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL21440782 | 0.76 | NPSR1 (0.63) | CACNA1GGAANPSR1 | |
| SCHEMBL8268615 | 0.75 | CACNA2D1 (0.71) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | claimed |
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | CACNA1D, CACNA1E, CACNA1B | CACNA1G 14/4885GAA 566/4885CACNA2D1 21/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA1G 5/4885GAA 1331/4885CACNA2D1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.